NCT03686709 Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
| NCT ID | NCT03686709 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Tennessee |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2018-06-19 |
| Primary Completion | 2019-06-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2018-06-19 with a primary completion date of 2019-06-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study * Must be able to schedule and tolerate additional PET/CT imaging following therapy * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure. Exclusion Criteria: * Patients that are not candidates for Y90 radioembolization therapy * Patients that cannot tolerate additional imaging procedures following therapy * Patients that cannot tolerate the additional blood draws required for this study * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study
Contact & Investigator
Dustin Osborne, PhD
PRINCIPAL INVESTIGATOR
University of Tennessee
Frequently Asked Questions
Who can join the NCT03686709 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03686709 currently recruiting?
Yes, NCT03686709 is actively recruiting participants. Contact the research team at dosborne@utmck.edu for enrollment information.
Where is the NCT03686709 trial being conducted?
This trial is being conducted at Knoxville, United States.
Who is sponsoring the NCT03686709 clinical trial?
NCT03686709 is sponsored by University of Tennessee. The principal investigator is Dustin Osborne, PhD at University of Tennessee. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.